JOP20200161A1 - أجسام مضادة أحادية النسيلة وطرق استخدامها - Google Patents

أجسام مضادة أحادية النسيلة وطرق استخدامها

Info

Publication number
JOP20200161A1
JOP20200161A1 JOP/2020/0161A JOP20200161A JOP20200161A1 JO P20200161 A1 JOP20200161 A1 JO P20200161A1 JO P20200161 A JOP20200161 A JO P20200161A JO P20200161 A1 JOP20200161 A1 JO P20200161A1
Authority
JO
Jordan
Prior art keywords
cell receptors
monoclonal antibodies
antibody
family
methods
Prior art date
Application number
JOP/2020/0161A
Other languages
English (en)
Inventor
Sergey Anatolievich Lukyanov
Olga Vladimirovna Britanova
Mark Aleksandrovic Izraelson
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of JOP20200161A1 publication Critical patent/JOP20200161A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

أجسام مضادة أحادية النسيلة وطرق استخدامها الملخص يتعلق الاختراع بأجسام مضادة أحادية النسيلة والتي ترتبط على وجه التحديد بالعائلة TRBV9 من مستقبلات الخلايا التائية البشرية. يتعلق الاختراع أيضاً بحمض نووي والذي يقوم بترميز الجسم المضاد المذكور أو شظية منه رابطة لمولد الضد، كما يتعلق بناقل تعبير وراثي، وبطريقة لإنتاج الجسم المضاد، وباستخدام الجسم المضاد المذكور لعلاج أمراض واضطرابات ترتبط بعائلة مستقبلات الخلايا التائية البشرية. يتم توجيه الاختراع نحو إنتاج أجسام مضادة والتي يمكن استخدامها للتخلص من مستقبلات الخلايا التائية من العائلة TRBV9 التي تحمل الخلايا التائية، وبالأخص لعلاج التهاب الفقار اللاصق، الداء البطني، وسرطانات الدم، والتي يشارك في إمراضها مستقبلات الخلايا التائية للعائلة TRBV9.
JOP/2020/0161A 2017-12-25 2018-12-25 أجسام مضادة أحادية النسيلة وطرق استخدامها JOP20200161A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2017145662A RU2694412C9 (ru) 2017-12-25 2017-12-25 Моноклональные антитела и способы их применения
PCT/RU2018/050168 WO2019132738A1 (ru) 2017-12-25 2018-12-25 Моноклональные антитела и способы их применения

Publications (1)

Publication Number Publication Date
JOP20200161A1 true JOP20200161A1 (ar) 2022-10-30

Family

ID=67002533

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0161A JOP20200161A1 (ar) 2017-12-25 2018-12-25 أجسام مضادة أحادية النسيلة وطرق استخدامها

Country Status (20)

Country Link
US (2) US11597767B2 (ar)
EP (1) EP3733705A4 (ar)
JP (1) JP7339948B2 (ar)
KR (1) KR20200103774A (ar)
CN (1) CN111801354A (ar)
AU (1) AU2018398341A1 (ar)
BR (1) BR112020012959A2 (ar)
CA (1) CA3086849A1 (ar)
CL (1) CL2020001726A1 (ar)
CR (1) CR20200324A (ar)
EA (1) EA202091569A1 (ar)
EC (1) ECSP20039728A (ar)
JO (1) JOP20200161A1 (ar)
MA (1) MA50128B1 (ar)
MX (1) MX2020006736A (ar)
NI (1) NI202000051A (ar)
PH (1) PH12020551012A1 (ar)
RU (1) RU2694412C9 (ar)
WO (1) WO2019132738A1 (ar)
ZA (1) ZA202003858B (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845797B2 (en) 2018-07-03 2023-12-19 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
RU2712251C1 (ru) * 2018-12-25 2020-01-27 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
RU2711871C1 (ru) 2018-12-25 2020-01-23 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела, которые специфически связываются с участком бета цепи семейства TRBV-9 Т-клеточного рецептора человека, и способы их применения
WO2024039268A1 (ru) * 2022-08-18 2024-02-22 Акционерное общество "БИОКАД" Способ лечения заболевания, опосредованного т-лимфоцитами

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766947A (en) 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US5223426A (en) 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
WO2010151416A1 (en) * 2009-06-25 2010-12-29 Fred Hutchinson Cancer Research Center Method of measuring adaptive immunity
EP3202784A1 (en) * 2016-02-08 2017-08-09 Polybiocept AB T-cell receptor sequences for active immunotherapy
JP6952225B2 (ja) * 2016-03-18 2021-10-20 北海道公立大学法人 札幌医科大学 Ｔ細胞レセプターとその利用
KR102436129B1 (ko) * 2016-06-17 2022-08-26 메디진 이뮤노테라피스 게엠바하 T 세포 수용체 및 이의 용도

Also Published As

Publication number Publication date
RU2017145662A3 (ar) 2019-06-25
RU2017145662A (ru) 2019-06-25
US20200332003A1 (en) 2020-10-22
KR20200103774A (ko) 2020-09-02
EP3733705A4 (en) 2021-09-01
MX2020006736A (es) 2020-08-24
CA3086849A1 (en) 2019-07-04
JP2021509274A (ja) 2021-03-25
MA50128A1 (fr) 2021-07-29
EA202091569A1 (ru) 2021-02-11
ZA202003858B (en) 2021-07-28
CL2020001726A1 (es) 2021-03-05
CN111801354A (zh) 2020-10-20
CR20200324A (es) 2020-10-08
ECSP20039728A (es) 2020-08-31
NI202000051A (es) 2021-12-16
US20230357396A1 (en) 2023-11-09
JP7339948B2 (ja) 2023-09-06
RU2694412C2 (ru) 2019-07-12
BR112020012959A2 (pt) 2020-12-01
WO2019132738A1 (ru) 2019-07-04
AU2018398341A1 (en) 2020-07-30
RU2694412C9 (ru) 2019-09-18
PH12020551012A1 (en) 2021-09-01
US11597767B2 (en) 2023-03-07
EP3733705A1 (en) 2020-11-04
MA50128B1 (fr) 2022-09-30

Similar Documents

Publication Publication Date Title
PH12020551012A1 (en) Monoclonal antibodies and methods for using same
MX2020008075A (es) Anticuerpos anti-ctla4 y métodos para elaborarlos y usarlos.
EA201792221A1 (ru) Антитела против сортилина и способы их применения
MD3313884T2 (ro) Anticorpi anti-CD123 şi conjugaţi şi derivaţi ai acestora
PE20180499A1 (es) Anticuerpos de union a tau
EA201692192A1 (ru) СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
NZ727024A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
AR084210A1 (es) PROTEINAS DE UNION AL TNF-a
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
PH12021551535A1 (en) Monoclonal antibodies that bind specifically to human trbv9
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
MX2019011520A (es) Anticuerpos anti antigeno leucocito 37 (cd37) biespecificos, anticuerpos anti antigeno leucocito 37 (cd37) monoclonales y metodos de uso de los mismos.
MY184189A (en) Methods of treating nail and scalp psoriasis
PH12020550596A1 (en) Antibodies and antibody-drug conjugates specific for cd123 and uses thereof
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
PH12019500342A1 (en) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6
ZA202008095B (en) Humanized antibodies against psma
PH12021551532A1 (en) Monoclonal antibodies against the beta chain region of human trbv9
EA201891800A1 (ru) Антитела к цитруллинированным hla-полипептидам и их применение
MX2021003756A (es) Composiciones farmaceuticas que comprenden anticuerpos anti cumulo de diferenciacion 37 (cd37) biespecificos.
MX2022008745A (es) Anticuerpos anti-nkp30 y metodos de uso.
EA202191139A1 (ru) АНТИТЕЛА К EpCAM, АКТИВИРУЕМЫЕ АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И ИХ ПРИМЕНЕНИЕ
ECSP19018367A (es) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6